文献速递前列腺癌

局部晚期前列腺癌超扩大机器人根治术技术改良

Technical Refinements in Superextended Robot-assisted Radical Prostatectomy for Locally Advanced Prostate Cancer Patients at Multiparametric Magnetic Resonance Imaging.
PubMed 文献 · Eur Urol · 2020-09-14

单中心分析89例MRI后侧iT3a或iT3b前列腺癌患者行超扩大机器人辅助根治性前列腺切除术(SE-RARP)的围手术期与随访结果,中位随访19个月,2年无生化复发生存55%,1年尿控恢复84%,病理分级分组4-5与切缘阳性为复发独立预测因素。

要点

  • SE-RARP适用于术前MRI后侧iT3a或iT3b患者,围手术期并发症与尿控恢复可接受
  • 病理GG 4-5与切缘阳性独立预测复发及追加治疗
  • 低级别且切缘阴性者可能获得生化控制并推迟追加治疗

核心结论

  • SE-RARP可用于术前MRI后侧iT3a或iT3b的前列腺癌患者,并发症与尿控恢复良好。
  • 该技术可能为低级别且切缘阴性患者保证生化控制并推迟追加治疗。

研究设计与样本

  • 单中心高流量中心2015-2018年89例后侧iT3a或iT3b行SE-RARP患者,78例有完整随访数据。
  • 采用DaVinci Xi系统,行筋膜内或筋膜外RARP,游离Denonvilliers筋膜与直肠周围脂肪并保留于精囊后表面。
  • 采用Kaplan-Meier与多因素Cox回归模型分析。

主要发现

  • 中位手术时间204 min,出血量300 ml,住院5 d,膀胱导尿5 d。
  • 病理GG 4-5、pT3b、切缘阳性分别占28%、28%、27%,术中并发症3例(3.4%)。
  • 78例随访患者中14例(18%)发生30 d术后并发症,中位随访19 mo。
  • 2年无生化复发生存55%,无追加治疗生存66%,1年尿控恢复84%。
  • 病理GG 4-5(HR 3.2)与切缘阳性(HR 5.8)为复发独立预测因素,追加治疗HR分别为5.6与5.2。

关键数值与推荐

  • 生化复发定义为连续两次PSA≥0.2 ng/ml。
  • 尿控恢复定义为使用零或一块安全垫。

临床怎么用

  • 对术前MRI后侧iT3a或iT3b患者可考虑SE-RARP,由经验丰富术者实施。
  • 术后依据病理GG与切缘状态评估复发与追加治疗风险。

局限性

  • 单中心、回顾性设计,样本量有限(89例,随访78例)。
  • 中位随访仅19 mo,长期肿瘤学结局待验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The feasibility and efficacy of robot-assisted radical prostatectomy (RARP) in locally advanced prostate cancer (PCa) patients with iT3 lesion at magnetic resonance imaging (MRI) are currently not explored. OBJECTIVE: To describe our revised RARP technique (ie, superextended RARP [SE-RARP]) for PCa patients with posterior iT3a or iT3b at MRI. DESIGN, SETTING, AND PARTICIPANTS: Data from 89 patients with posterior iT3a or T3b disease who underwent SE-RARP at a single high-volume centre between 2015 and 2018 were analysed. SURGICAL PROCEDURE: RARP was performed using a DaVinci Xi system. The surgical approach provided an inter- or extrafascial RARP where Denonvilliers' fascia and perirectal fat were dissected free and left on the posterior surface of the seminal vesicles. MEASUREMENTS: Perioperative outcomes, and intra- and postoperative complications were assessed. Postoperative outcomes were assessed in patients with complete follow-up data (n = 78). Biochemical recurrence (BCR) was defined as two consecutive prostate-specific antigen values of ≥0.2 ng/ml. Urinary continence (UC) recovery was defined as the use of zero or one safety pad. Kaplan-Meier and multivariable Cox regression models were used. RESULTS AND LIMITATIONS: The median operative time, blood loss, and length of stay were 204 min, 300 ml, and 5 d, respectively. The median bladder catheterisation time was 5 d. Overall, 28%, 28%, and 27% of patients had pathological grade group (GG) 4-5, pT3b, and positive surgical margins (PSMs), respectively. Three patients (3.4%) experienced intraoperative complications. Among patients with available follow-up data (n = 78), 14 (18%) experienced 30-d postoperative complications. The median follow-up was 19 mo. Overall, 11 patients received additional treatment. At 2 yr of follow-up, BCR-free and additional treatment-free survival were 55% and 66%, respectively. Pathological GG 4-5 (hazard ratio [HR] 3.2) and PSM (HR 5.8) were independent predictors of recurrence, as well as of additional treatment use (HR 5.6 for GG 4-5 and 5.2 for PSM). The 1-yr UC recovery was 84%. CONCLUSIONS: We presented our revised RARP technique applicable to patients with posterior iT3a or iT3b at preoperative MRI. This technique is associated with good morbidity and continence recovery rates, and might guarantee biochemical control of the disease and postpone the use of additional treatments in patients with low-grade and negative surgical margins. PATIENT SUMMARY: A revised robot-assisted radical prostatectomy technique applicable to prostate cancer patients with posterior iT3a or iT3b lesion at magnetic resonance imaging was described. This novel technique is feasible and safe in expert hands.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Mazzone E, Dell'Oglio P, Rosiello G, et al. Technical Refinements in Superextended Robot-assisted Radical Prostatectomy for Locally Advanced Prostate Cancer Patients at Multiparametric Magnetic Resonance Imaging. Eur Urol. 2020. PMID: 32943260. doi:10.1016/j.eururo.2020.09.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。